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Artificial intelligence (AI) researchers claim that they have made great ‘achievements’ in
clinical realms. However, clinicians point out the so-called ‘achievements’ have no ability to
implement into natural clinical settings. The root cause for this huge gap is that many essen-
tial features of natural clinical tasks are overlooked by AI system developers without medi-
cal background. In this paper, we propose that the clinical benchmark suite is a novel and
promising direction to capture the essential features of the real-world clinical tasks, hence
qualifies itself for guiding the development of AI systems, promoting the implementation of
AI in real-world clinical practice.
AI researchers claim that they have obtained many significant ‘achievements’ in various
realms of clinical medicine, i.e., cancer diagnosis 1, 2. However, in practice, most of the AI products
fail to obtain approval from the Food and Drug Administration (FDA). Moreover, the approved AI
products, which are quite rare, are only limited to class II or I1, which means that even the approved
AI devices are not qualified handling high-risk tasks such as clinical diagnosis2. Question marks
hang over the AI systems for real-world clinical tasks. Why is there such a huge gap between the AI
research and AI implementation in natural clinical setting? How to promote the AI implementation
into natural clinical settings to bridge the gap?
The common interpretation, given by the clinicians, for this huge gap is that many technical
issues in clinical settings remain unsolved, leading to the inability of the AI system in natural
clinical settings, and that the AI researchers overestimate the ability of AI system validated in the
artificially designed experiments 4, 5. In order to uncover the essential reasons for the gap mentioned
above, our team, consisting of AI researchers and clinicians, analyzed the development process of
AI systems and give the following explanation. The features of clinical tasks in natural settings
are ignored in the entire lifecycle (design, implementation, and evaluation) of the AI systems,
thus the generated AI system itself has no ability to be implemented in natural clinical settings.
1Medical devices are classified into one of three classes based on the degree of risk they present 3. The instances
for class I, II and III are manual toothbrush, male condoms and heart valve respectively.
2Since the clinical diagnosis is the base or evidence to the treatment or further action of patient, the incorrect
diagnosis may lead to serious consequences.
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For example, when the related diseases with similar symptoms are omitted, the AI system cannot
directly handle the patients in natural clinical settings3. Another example is that when the natural
ratio between disease-positive and disease-negative subjects is omitted, a risk of spectrum bias and
thus the inflated diagnostic or predictive performance will be brought about 6. Thus, it is imperative
to capture the essential features of the real-world clinical tasks to guide the entire lifecycle of the
AI system and promote its implementation and wide adoption in natural clinical settings.
In the computer community, a domain or application-specific benchmark suite serves as a
highly valuable tool to capture real features of the tasks, simulate the tasks in real world, guide
the development process, and finally evaluate the system under test. Inspired by its great success,
we strongly believe that the clinical benchmark suite holds the power to improve the design and
implementation of AI systems and enables the AI researches to smoothly ‘touch down’ in the
real clinical practice. In the future, the clinical benchmark suite built with the joint efforts of
the AI researchers and clinicians will play a significant role in the whole development process
of the AI systems, and promote the implementation of AI systems in real clinical settings. The
clinical benchmark suite will run throughout the entire lifecycle of the AI system to promote the
embedment of AI systems in the current healthcare system. In this way, the AI system will be
able to reduce the workload of clinicians, improve the skill of junior clinicians, give precaution
and inform the patients to seek the medicine services further in hospitals, and provide preliminary
healthcare service in the rural areas.
State-of-the-art and state-of-the-practice in clinical settings.
In general, AI technologies went through three periods: expert system, traditional machine
learning, and deep learning 7–9. However, AI systems have hardly been implemented in natural
clinical settings, in spite of their plentiful great results achieved in research.
State-of-the-art. AI technologies have achieved many ‘achievements’ in various realms of clinical
medicine such as cancer 10–12, cardiovascular diseases 13–15 and retinopathy 16–18. In a natural
clinical setting, each clinical diagnosis task is flexible, and usually consists of several different
sub-tasks according to each individual patient. Currently, most reported AI systems outperform
the human experts only in certain specific sub-tasks, especially in the medicine imaging area.
For example, Esteva et al. 10 developed a deep convolutional neural network model to classify
skin lesions in a task, which was divided into two sub-tasks. One sub-task was to classify the skin
lesions into three categories: benign lesions, malignant lesions, and non-neoplastic. As a result, the
system defeated the dermatologists (accuracy of 65.78± 0.22%) with an accuracy of 72.1± 0.9%.
The other sub-task was to classify the skin lesions into nine categories, the patients of which have
similar medical treatment plans. In this sub-task, the model defeated the dermatologists (accuracy
of 54.15± 0.85%) with an accuracy of 55.4± 1.7%.
State-of-the-practice. We discuss the state-of-practice from two aspects: the listing qualification
and the application performance in a real environment.
In contrast with the plentiful successful AI researches on the clinical tasks, there are few AI
products that have obtained FDA approval (Table 1) 19, 20, though FDA (the Listing qualification
3The patients with the omitted diseases usually appear in the clinical settings.
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Table 1: AI medical devices approved by FDA.
Approval Date Device Function RegulatoryClass
Submission
Type
December 2018 ProFound AI
Detection and diagnosis
of suspicious lesions II 510(k)
December 2018 ReSET-O
Adjuvant treatment of
substance abuse disorder II 510(k)
December 2018 Embrace Epilepsy detection II 510(k)
November 2018 Icobrain Brain structure interpretation II 510(k)
October 2018 Accipiolx
Acute cerebral
hemorrhage diagnosis II 510(k)
September 2018
Irregular Rhythm
Notification Feature Atrial fibrillation detection II De Novo
September 2018
RightEye
Vision System
Identify visual
tracking impairment II 510(k)
August 2018 BriefCase
Prioritization,
triage and diagnosis of
time sensitive patient
II 510(k)
August 2018
PhysiQ Heart
Rhythm Module
Atrial fibrillation detection
and analysis engine II 510(k)
June 2018 POGO
Automatic blood
glucose monitoring system II 510(k)
June 2018 HealthCCS
Coronary artery calcification
detection and quantification II 510(k)
June 2018
DreaMed
Advisor Pro
Suggestions for parameter
adjustment of insulin pump II De Novo
May 2018 NeuralBot
Transcranial
Doppler probe positioning II 510(k)
May 2018 MindMotion GO Motion capture for the elderly II 510(k)
May 2018 EchoMD AutoEF
Left ventricular
ejection fraction estimation II 510(k)
May 2018 OsteoDetect
Identification of
distal radius fractures II De Novo
April 2018 IDX-DR Screening for diabetic retinopathy II De Novo
Feburary 2018 ContaCT
LVO large blood
vessel blockage warning II De Novo
January 2018 Embrace Epilepsy detection II 510(k)
January 2018
Arterys
Oncology DL
Volumetric segmentation of
lung nodules and liver lesions II 510(k)
December 2017 BioFlux Arrhythmia detection II 510(k)
November 2017
Kardia
Band System Cardiac arrhythmias detection II 510(k)
July 2017 QuantX
Assessment and characterization
of breast abnormalities II De Novo
May 2017 AmCAD-US
Visualization and quantitative
analysis of thyroid nodules II 510(k)
March 2017 EnsoSleep Diagnosis of sleep disorders II 510(k)
Feburary 2017
Arterys
Cardio DL
Visualization of cardiac structure,
quantification of cardiac function II 510(k)
January 2017 Cantab Mobile
Memory
problem assessment
tool for the elderly
II 510(k)
November 2016
One Drop
Blood Glucose
Monitoring System
Quantification of
blood glucose levels II 510(k)
October 2016 Lumify
Ultrasound image diagnosis
and fluid flow analysis II 510(k)
July 2016 InPen Determine the insulin dose II 510(k)
March 2016 QbCheck
Diagnosis
and treatment of ADHD II 510(k)
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institution) downgraded its regulatory requirements for AI product approval. What’s more, the
existing AI products with FDA approval are incompetent to provide the evidence or basis for the
decision of the treatment of the serious diseases for the following reasons.
a) Most of the incorrect decisions of the treatment may cause the enormous loss to the patients.
b) All approved AI products, which are only classified into the class II or I, are not qualified for
handling the tremendous risk, since it is stipulated by FDA that medical devices with high
risk should be classified into class III and subject to the strictest supervision.
For example, although the first autonomous AI diagnostic system IDx-DR authorized by the FDA
is able to give suggestions to a patient after diagnosis 21, the suggestions4 cannot apply to guide
the treatment according to the FDA. What’s more, none of the successful AI researches on clinical
tasks have obtained the approval from China Food and Drug Administration (CFDA), despite the
fact that the Chinese government is eager to use AI to improve the national healthcare.
In the real clinical practice, the AI technologies are far from satisfactory. For example, it
was pointed out that many of recommendations for treatment from the Watson for Oncology, the
most famous AI product, were erroneous 20. In a randomized controlled trial, Brocklehurst et al. 22
reported that the widely-used continuous electronic fetal heart rate monitoring technology did not
reduce the number of poor neonatal outcomes in the real clinical practice. Kanagasingam et al. 23
evaluated an AI system serving to identify diabetic retinopathy in clinical practice. As a result, the
positive predictive value was 12% (95% CI, 8%-18%), though the specificity was 92% (95% CI,
87%-96%).
Based on the above analysis, it has to be admitted that the AI is currently seeing too much
hype, and a strict evaluation system is urgently needed to evaluate the clinical value of currently
AI system in real clinical practice 5, 20, 24–29.
The interpretation for the plight of practical implementation of AI.
Currently, the AI systems are developed and validated based on the artificially constructed datasets.
However, the natural clinical setting is open, containing many unpredictable factors. Thus, there
are many technical issues worth considering before the practical implementation of AI, which is
consistent with the views of the clinicians.
The technical issues, which were proposed by clinicians, are roughly divided into five cate-
gories 4, 30: A) the uncertainty and complexity of clinical tasks in natural clinical settings, B) the
metrics of the benefit of the patients, C) the evaluation baselines of the AI systems, D) the repro-
ducibility of the AI system. E) the interpretability of the AI systems. Among them, the issues
of reproducibility and interpretability attracted intensive attention from the AI researchers 31, with
many significant achievements 17, 32. In contrast, the first three types of issues (categories A, B, and
C) received relatively less research attention, and have been the cruxes to the implementation of
the AI researches into natural clinical settings.
For example, Esteva et al. 10 claimed that the AI system (a deep convolutional neural net-
work model) defeated the dermatologists in the task of classifying skin lesions, while Mar et al. 33
4The incorrect suggestion may lead to delay of further treatment and loss of vision, which is an enormous risk that
the medical device with class II is not qualified to handle.
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pointed out that the AI system still needed to solve many issues before it cam be put into practical
application. The main items are as follows: 1) Integrating patient information (Category A), i.e.,
the history of the lesion, to improve the performance of the AI system. 2) Identifying skin cancers
the patient is unaware of5 (Category A). 3) Validating the AI system in a natural clinical setting
(Category C). 4) Proving the benefit of the AI system (Category B), such as the reduction in
melanoma mortality. In addition, Adamson et al. 34 pointed out another issue to be addressed for
the AI system: it should hold the inclusivity to handle different types of skin (Category A), i.e.,
skins with different colors.
The issues proposed by the clinicians urge us to uncover the root cause for the current plight
of the practical implementation of AI to promote its implementation in natural clinical settings.
A new reason for the plight of the practical implementation of AI.
In order to uncover the root cause for the plight of AI in natural clinical settings, we successively
analyze and summarize the development process of a specific AI system 10, the development pro-
cess of a general AI system, and the clinical task in a natural clinical setting.
The development process of a specific AI system. In the design, implementation, and evaluation
of the AI system on skin cancer classification by Esteva et al. 10, the features of natural clinical
setting were omitted as follows in order to simplify the clinical task.
a) Design: 1) The types of disease of patients are limited. For example, the epidermal lesion
must belong to one of the following diseases, malignant basal and squamous cell carcinomas,
intraepithelial carcinomas, pre-malignant actinic keratosis and benign seborrheic keratosis.
2) The comorbidity was ignored by assigning only one label for an individual patient. It
means that the patient has to obtain an exact primary diagnosis before getting access to the
AI system.
b) Implementation: Only image was selected as the patient information. Though the accuracy
of the classification of skin lesions was only 55.4 ± 1.7%, Esteva et al. 10 did not integrate
other relevant information, such as history of the lesion, to improve the accuracy of the AI
system.
c) Evaluation: Issues regarding the evaluation of the AI system are as follows: 1) The AI system
was validated on a carefully constructed dataset, which ignored the features of a natural clin-
ical setting. For example, a number ratio of 169 : 207 for malignant vs. benign melanocytic
lesions was used in a test dataset, while malignant melanocytic lesions are exceedingly rare
compared with benign melanocytic lesions in reality. 2) An unfair baseline was actually con-
structed. The skin lesions diagnosis is an open task in a natural clinical setting, in which the
dermatologists will do their best (even including biopsy) to obtain a diagnosis as accurate
as possible for each individual patient. Thus, it is unfair for a clinician to make a diagnosis
only based on images. 3) The benefit of patients were ignored. Esteva et al. 10 did not prove
the benefit, such as the reduction in melanoma mortality, of the patients.
5The AI model only has the ability to identify the cancers which are contained in train set. Usually, the AI
researcher will carefully construct the train set, and the train set only contains a few numbers of diseases.
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Fig. 1. The development workflow of an AI clinical system. For the AI system, first, the re-
searchers collect the relevant information of a clinical diagnosis task from a variety of sources.
Second, the data are preprocessed for the model, which includes data selection, data cleaning, data
enhancement et al. Finally, the data are divided into a training data set, a validation data set, and
a test data set. The training data set and validation data set are used to recurrently train and select
the best model, and the test data set is used to evaluate the AI system or AI model.
Based on the above analysis. it is evident that many important features of the real-world
clinical tasks are omitted during the development of this specific AI system, which makes it difficult
to be implemented in the complex and uncertain clinical settings, arousing the aforementioned
issues concerned by many clinicians.
The development process of a general AI system. In order to demonstrate the universal existence
of the concerned issues of the state-of-the-art AI systems in a natural clinical setting, we herein
discuss a clinical diagnosis task in which a general AI system was used without considering a
specific disease. Currently, the AI researchers usually simplify a specific clinical diagnosis task in
the stage of data collection and data preparation (Fig 1) 24 for the AI system to achieve excellent
performance. The issues are as follows.
a) The task is simplified by the AI developers. The following facts can be observed in the state-
of-the-art researches. 1)Excluding related disease that co-occurs with the target disease.
2)Ignoring the comorbidity. 3)Ignoring the so-called ‘bad data’.
b) The patient data are carefully selected by the AI researchers, which ensures that each patient
has the same type of data, meaning that the patients have the same diagnosis procedure
before the therapy. Besides, the selected data usually are incomplete and hardly represent
the full health status of a patient.
c) The evaluation is usually performed in a well-designed and restricted environment.
Apparently, many important features are omitted by the AI researchers, i.e., the natural ratio be-
tween disease-positive and disease-negative 6, during the development of the AI system.
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Fig. 2. The classical workflow of clinical diagnosis vs. the workflow of clinical diagnosis with
current AI systems, which is rigid and disconnected with clinician-centered healthcare sys-
tems. a, In a natural clinical setting, first, a patient visits the clinician according to their experience
or the suggestion of the guide nurses. Second, the clinician acquires the necessary information
from the patient. Finally, the clinician makes a decision for the patient according to the known
information, professional knowledge and clinical experience. The decision includes three options:
carry out further examination, referral and make a diagnosis. b, Currently, the AI system is hardly
connected into the diagnosis process in natural clinical settings, as many important features of
the clinical task are omitted. First, the AI system cannot directly handle various patients from
the clinical setting, since many diseases are omitted by the AI researcher. The clinicians have to
make a primary diagnosis and select the proper patients for the AI system. Second, the AI system
cannot directly handle the selected patients, since lots of patient information is omitted by the AI
researcher. The clinicians have to divide the clinical diagnosis into several sub-tasks, and select
a proper AI system for each specific sub-task. Third, the AI system cannot provide personalized
diagnosis plan for each individual, since the AI system is usually rigid in that it can only handle
the same type of data. Finally, the AI system cannot directly diagnose a patient, since the clinical
value of the AI system is questionable and is in an urgent need for validation in a scientific way.
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The clinical tasks in a natural setting. As mentioned, a natural clinical setting is open and the
diagnosis itself is flexible 35, and a clinical diagnosis task is a very complex and uncertain owing
to the following reasons.
a) Affected by the subtle difference in terms of experience and knowledge of the patients, their
decisions to select clinicians hold great uncertainty. As a result, the patients that have the
same disease may choose different clinicians and the patients that have different diseases
may go to the same clinician.
b) Comorbidity is commonly observed in a patient. For example, Caspi et al. 36 pointed out that
among individuals meeting the criteria for one psychiatric disorder in their life time, 66%
met the criteria for a second one; of those meeting criteria for two disorders, 53% met the
criteria for a third one; of those meeting the criteria for a third disorder, 41% met criteria for
a fourth one 36. Thus, comorbidity is an important factor that needs to be taken into account.
c) It is a consensus that many diseases have various subtypes, and different subtypes or stages
of the disease may be subject to different therapeutic plans 37. Thus, the final diagnosis made
by the clinicians should be able to directly, accurately and duly help to select appropriate and
effective therapeutic plans for the patient.
d) The workflow of a diagnosis task is flexible according to each individual situation. For
example, different patients may be required to perform different examinations.
e) The data sources and types of a patient are usually multifarious and integrated, and the
knowledge from different sources must be comprehensively considered 35.
f) The diagnosis is patient-centered in clinical settings. Thus, the evaluation of diagnosis must
reflect the benefit of patients, such as downstream outcomes (overall survival) 38.
In a word, a clinical diagnosis task is complex and uncertain. The root cause for the current
plight of the practical implementation of AI is that the essential features of clinical tasks in natural
clinical settings are often omitted by AI researchers, as we discuss above.
What is wrong with the state-of-the-art AI systems in natural clinical settings. Currently,
the clinician has to deal with massive complex and uncertain clinical tasks with their skill and
experience (Fig 2a). Thus, it is highly urgent for clinicians to cooperate with AI systems to pro-
vide high-quality, high-efficiency, and low-cost healthcare solutions. Disappointedly, current AI
systems show little help with regard to improving the quality of medical care and reducing the
workload of clinician due to the following reasons (Fig 2b) :
1) Currently, the AI system is far from intelligent to be embedded in the current health system,
as many important features of the clinical tasks have not been considered. The AI system
only has ability to handle a few specific sub-tasks (such as the identification of medical
imaging) of a clinical diagnosis carefully preprocessed by clinicians, which instead increases
the workload of the clinicians (Fig 2b).
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2) As a clinical diagnosis task usually consists of complex sub-tasks, the clinician needs to
comprehensively consider the complete diagnosis task rather than only consider one or two
specific sub-tasks, which the AI system is competent for handling. Thus, the outcome of the
AI system is not appealing to the clinicians.
3) For the lack of scientific evaluation of clinical value, the AI systems are forbidden to deliver
diagnosis for patients.
It is essential and significant for the AI researchers to comprehensively understand the tasks
in the natural clinical settings so that they are able to improve the design and implementation of the
AI systems to cope with complex and uncertain tasks in natural clinical settings. In addition, the
scientific metrics and baselines are essential to evaluate the clinical value of an AI system before
it is implemented in clinical settings.
A new direction to promote the practical implementation of AI in medicine
Though the AI researchers claim that their AI systems have outstanding performance, their systems
are still hardly implemented in natural clinical settings for ignoring the essential features of the
clinical tasks. Fortunately, a clinical benchmark suite has great potential to capture the features of
the clinical tasks and scientifically evaluate the performance of an AI system, thus promoting AI
systems embed in healthcare system.
Benchmark suite. In computer science, the benchmark suite is a powerful tool to simulate the
workloads in the real world and evaluate the performance of the systems using the simulated work-
loads 39. On one hand, it reproduces the real workloads to help the developers comprehensively
understand the real workload and improve their system design and implementation to cope with
complex and uncertain workloads in the real world. On the other hand, it provides a scientific
evaluation methodology and tool to objectively evaluate the system under test and guide the de-
veloper to improve the system. The benchmark suite has been successfully applied in many areas
and attracted intensive research attention. Guthaus et al. 40 presented a benchmark suite for the
CPU evaluation. Wang et al. 41 presented a comprehensive big data benchmark suite, named Big-
DataBench, for the architecture and system evaluation. Geiger et al. 42 constructed a vision bench-
mark suite, named KITTI, for autonomous driving evaluation. Thus, we strongly believe that the
clinical AI benchmark suite holds the potential to promote the implementation of AI systems in
natural clinical settings.
The future of an AI system with a clinical benchmark suite. Inspired by the successes of AI
in various realms, we are optimistic that AI has potential to improve the quality of healthcare.
However, as the specialty of healthcare (involve our health), we believe that AI system should be
harmoniously embedded in the current healthcare systems to cooperate with clinicians to provide
high quality and low cost of medical service instead of replacing clinicians. And, it is the key
to help the AI researchers capture the features of the clinical tasks, improve the design of the
AI system and optimize the implementation of the AI system, and promote the AI systems to be
harmoniously embedded in the current healthcare system.
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Fig. 3. The future AI system in medicine. In the future, the first thing is the cooperation between
AI researchers and specialists with different backgrounds to iteratively construct a clinical bench-
mark suite. Secondly, the AI researchers iteratively develop and verify AI systems based on the
benchmark suite. Finally, after the AI systems is approved by the regulator, they will be deployed
in a natural clinical setting to provide high-quality medical care. The AI systems will play an
important role in at least three classic scenarios. 1) In cooperation with senior clinicians: the AI
systems will act like a clinician as shown in Fig 2a, and send the diagnostic task beyond its ability
to the senior clinician. On one hand, the senior clinician reviews the diagnosis from an AI system;
On the other hand, the senior clinician is in charge of the diagnostic tasks that cannot be handled
by an AI system. In addition, the senior clinician can cooperate with the specialists from different
backgrounds to update the benchmark suite with respect to the development of medicine and the
change of the clinical settings. 2) In cooperation with junior clinicians: different from the first
scenario, the junior clinicians in this scenario will cooperate with the benchmark suite to review
the diagnosis of AI system, as the benchmark suite contains the ‘ground truth’ of different patients.
In this way, the benchmark suite helps the junior clinicians improve their skills. 3) Daily health
management, disease prevention, chronic disease management, out-of-hospital rehabilitation, and
healthcare services in rural areas: in this scenario, the AI system will give precaution and inform
the patients of seeking further medical service in hospital
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In the future, the clinical benchmark needs to be paid more attention, as it is expected to play
a significant role in the development of AI system. The clinical benchmark will run throughout the
entire lifecycle of the AI system in medicine (Fig 3) undertaking the following tasks: (1) help the
researchers understand the natural clinical settings and clinical tasks before the implementation
of an AI system, and finally promote the AI system to implement in a natural clinical setting,
(2) comprehensively test the performance of the AI system in a simulated clinical setting in the
development process, (3) provide evaluation indicators and baselines for the regulatory authorities.
In this way, AI system can be embedded in the current healthcare system. In addition, the AI system
will be able to A) reduce the workload of clinicians by automatically handling essential clinician
sub-tasks, B) improve the skill of junior clinician by providing a simulated clinical setting, C) give
precaution and inform the patients of further medicine service in hospital with regard to daily health
management, disease prevention, chronic disease management, and out-of-hospital rehabilitation,
and D) provide preliminary healthcare service in the rural areas.
The key issues of the research on clinical benchmarks. In the realm of medicine, the clinical
benchmark suite is a new conception. Thus, there are many key issues of the clinical benchmark
suite that must be investigated (Fig 4).
a) Data sets. Unlike the carefully-constructed data set for the current AI system, the data set in
the real clinical practice should contain all the diverse information (including so-called bad
data), which is conducive to the more accurate restoring of the natural clinical settings and
tasks.
b) Tasks. The task is the workload of the AI system in a natural clinical setting, where each
clinical diagnosis task is personalized and flexible according to each individual situation.
And the clinical diagnosis is continuous until the result of the diagnosis is able to effectively
guide the treatment. For most diseases there is no one-size-fits-all diagnosis task, and each
diagnosis task usually consists of several different sub-tasks according to each individual
patient.
c) Metrics. The purpose of the diagnosis is to obtain the evidence to assist the clinicians in
making the suitable and effective medical treatment plan for the patients. Thus, the metrics
must reflect the benefit of the selected treatment for the patient. However, the current metrics
of AI system (such as the accuracy of prediction) do not have such capabilities. Another
important issue is that current metrics cannot represent the standards although they can be
used as a reference 6, 38.
d) Baselines. The benchmark suite must include two baselines. One is the state-of-the-art base-
line that is used to evaluate the AI system from a research technical perspective. The other is
the state-of-the-practice baseline that is used by the clinicians in the natural clinical settings.
This baseline is used to evaluate the clinical value of the AI system from a perspective of
clinical practice.
Conclusion
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Fig. 4. The clinical benchmark suite. The benchmark suite consists of data sets, tasks, metrics
and baselines. The data sets contain the patient information from the real clinical practice. A
clinical diagnosis task is a flexible diagnosis process consisting of several sub-tasks. The metrics
consists of the patient benefit metrics and the other common performance metrics. The baselines
contain both state-of-the-art and state-of-the-practice methods.
AI systems are currently witnessing excessive hype of their ‘super power’ in medicine re-
search and thus capturing intensive attention of the public, which leads to the increasing expecta-
tion of public to used AI technologies to improve healthcare. However, current AI technologies
are far from being mature to be implemented in natural clinical settings, in spite of their rapid
advancement 28. And, many clinicians gradually losing faith in AI 22, 24, 29, 43. It is worth noting that
the increasing gap between the high expectation and unsatisfactory practical implementation of AI
technology is one of the main reasons why AI fell into the first trough. Hence, it is imperative
to actively promote the practical implementation of AI technology and objectively evaluate the
current AI technology. Inspired by the success of the benchmark in the computer communities,
we strongly believe that the clinical benchmark is a powerful tool to promote the AI technology
to be effectively applied in the real clinical practice, and provide an objective evaluation of the
current AI technologies. The clinical benchmark suite holds a promising future as a new direction
to promote the implementation of AI in clinical practice. Alike the animal models that play an
important role in the drug development process, a clinical benchmark suite will also play an im-
portant role spanning the whole lifecycle of an AI system for clinical tasks not only in the design,
implementation, and evaluation, but also in a natural clinical setting.
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